Drug intelligence / Profile preview

RT102

Development stage: Preclinical
Lead developer: RANI Therapeutics
Modality: CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration: Oral, Intraperitoneal

Overview

RT102 is a preclinical gene modulation therapy developed by Regel Therapeutics. It utilizes the company's proprietary T3 platform, also known as Targeted EpiEditing, which employs a non-editing, deactivated CRISPR system. This technology is designed to restore normal gene expression to treat genetic disorders. RT102 is specifically being advanced for the treatment of SCN2A Haploinsufficiency.

Targets

Sodium voltage-gated channel alpha subunit 2 gene regulatory region

Beyond the preview

Go deeper on RT102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT102.

Explore the full profile